Leif G Hanitsch1, Madlen Löbel2, Jan Florian Mieves2, Sandra Bauer2, Nina Babel3, Brunhilde Schweiger4, Kirsten Wittke2, Patricia Grabowski2, Hans-Dieter Volk5, Carmen Scheibenbogen5. 1. Institute of Medical Immunology, Charité University Medicine Berlin, Campus Virchow, Berlin, Germany. Electronic address: leif-gunnar.hanitsch@charite.de. 2. Institute of Medical Immunology, Charité University Medicine Berlin, Campus Virchow, Berlin, Germany. 3. Medical Clinic I, Marien Hospital Herne, Ruhr University Bochum, Herne, Germany; Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité University Medicine Berlin, Germany. 4. National Reference Centre for Influenza, Robert-Koch-Institute, Berlin, Germany. 5. Institute of Medical Immunology, Charité University Medicine Berlin, Campus Virchow, Berlin, Germany; Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité University Medicine Berlin, Germany.
Abstract
BACKGROUND: Immunization against seasonal influenza with inactivated vaccine is recommended for patients with common variable immunodeficiency (CVID). However, humoral vaccine response in CVID patients is frequently impaired and current knowledge on T cell vaccine response in CVID and other patients with antibody deficiency is poor. OBJECTIVE: In the present study, we comparatively analyzed the antibody and T cellular immune response of patients with CVID and unclassified antibody deficiency to influenza vaccination in the season 2013-2014. METHODS: Eight patients with CVID, 8 patients with unclassified antibody deficiency and 9 healthy controls were vaccinated with a single dose of non-adjuvanted seasonal influenza vaccine. Before and 3 weeks after the vaccination antibody titers against the strains A/California/7/2009, A/Texas/50/2012, and B/Massachusetts/02/2012 included in the vaccine were measured by hemagglutination inhibition testing. Additionally, vaccine-specific T cell cytokine response was determined by stimulation with the complete vaccine in vitro. RESULTS: Whereas all healthy controls responded to vaccination with serum antibody titers, only 1/8 CVID patients and 4/8 patients with unclassified antibody deficiency showed a response against at least 1 of the 3 vaccine strains. However, 7/8 of the CVID and 6/8 of the patients with unclassified antibody deficiency had similar frequencies of vaccine-induced IFN-γ, TNF-α and IL-2 producing CD40L(+) T cells as the control group. CONCLUSION: Our data suggest that most CVID and unclassified antibody deficiency patients benefit from seasonal influenza vaccination by mounting a cellular response.
BACKGROUND: Immunization against seasonal influenza with inactivated vaccine is recommended for patients with common variable immunodeficiency (CVID). However, humoral vaccine response in CVIDpatients is frequently impaired and current knowledge on T cell vaccine response in CVID and other patients with antibody deficiency is poor. OBJECTIVE: In the present study, we comparatively analyzed the antibody and T cellular immune response of patients with CVID and unclassified antibody deficiency to influenza vaccination in the season 2013-2014. METHODS: Eight patients with CVID, 8 patients with unclassified antibody deficiency and 9 healthy controls were vaccinated with a single dose of non-adjuvanted seasonal influenza vaccine. Before and 3 weeks after the vaccination antibody titers against the strains A/California/7/2009, A/Texas/50/2012, and B/Massachusetts/02/2012 included in the vaccine were measured by hemagglutination inhibition testing. Additionally, vaccine-specific T cell cytokine response was determined by stimulation with the complete vaccine in vitro. RESULTS: Whereas all healthy controls responded to vaccination with serum antibody titers, only 1/8 CVIDpatients and 4/8 patients with unclassified antibody deficiency showed a response against at least 1 of the 3 vaccine strains. However, 7/8 of the CVID and 6/8 of the patients with unclassified antibody deficiency had similar frequencies of vaccine-induced IFN-γ, TNF-α and IL-2 producing CD40L(+) T cells as the control group. CONCLUSION: Our data suggest that most CVID and unclassified antibody deficiencypatients benefit from seasonal influenza vaccination by mounting a cellular response.
Authors: Kathleen E Sullivan; Hamid Bassiri; Ahmed A Bousfiha; Beatriz T Costa-Carvalho; Alexandra F Freeman; David Hagin; Yu L Lau; Michail S Lionakis; Ileana Moreira; Jorge A Pinto; M Isabel de Moraes-Pinto; Amit Rawat; Shereen M Reda; Saul Oswaldo Lugo Reyes; Mikko Seppänen; Mimi L K Tang Journal: J Clin Immunol Date: 2017-08-07 Impact factor: 8.317
Authors: Gemma E Hartley; Emily S J Edwards; Julian J Bosco; Samar Ojaimi; Robert G Stirling; Paul U Cameron; Katie Flanagan; Magdalena Plebanski; Philip Mark Hogarth; Robyn E O'Hehir; Menno C van Zelm Journal: Clin Transl Immunology Date: 2020-10-16
Authors: Daniel Arroyo-Sánchez; Oscar Cabrera-Marante; Rocío Laguna-Goya; Patricia Almendro-Vázquez; Octavio Carretero; Francisco Javier Gil-Etayo; Patricia Suàrez-Fernández; Pilar Pérez-Romero; Edgard Rodríguez de Frías; Antonio Serrano; Luis M Allende; Daniel Pleguezuelo; Estela Paz-Artal Journal: J Clin Immunol Date: 2021-11-17 Impact factor: 8.317
Authors: Melissa R Stas; Michaela Koch; Maria Stadler; Spencer Sawyer; Elena L Sassu; Kerstin H Mair; Armin Saalmüller; Wilhelm Gerner; Andrea Ladinig Journal: Front Immunol Date: 2020-09-11 Impact factor: 7.561
Authors: Mikhail P Kostinov; Elena A Latysheva; Aristitsa M Kostinova; Nelly K Akhmatova; Tatyana V Latysheva; Anna E Vlasenko; Yulia A Dagil; Ekaterina A Khromova; Valentina B Polichshuk Journal: Vaccines (Basel) Date: 2020-11-02